Taysha Gene Therapies, Inc.
USD5.96
-0.01 (-0.17%)
CEO
Sean Nolan
IPO Date
2020-09-24
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$5.76
Prev. Close
$5.97
Day Low
$5.72
Day High
$6.12
52W Low
$2.34
52W High
$7.30
Market Cap
$1.49B
Volume
2.85M
| 21,335 |
| $0.00 |
| 2 Jun 2026 | Stalfort John A III | director | A-Award | Acquired | 42,671 | $5.97 |
| 2 Jun 2026 | Donenberg Phillip B. | director | A-Award | Acquired | 21,335 | $0.00 |
| 2 Jun 2026 | Donenberg Phillip B. | director | A-Award | Acquired | 42,671 | $5.97 |
| 2 Jun 2026 | Long Alison S | director | A-Award | Acquired | 21,335 | $0.00 |
| 2 Jun 2026 | Long Alison S | director | A-Award | Acquired | 42,671 | $5.97 |
| 2 Jun 2026 | Sepp-Lorenzino Laura | director | A-Award | Acquired | 21,335 | $0.00 |
| 2 Jun 2026 | Sepp-Lorenzino Laura | director | A-Award | Acquired | 42,671 | $5.97 |
| 13 Apr 2026 | Nagendran Sukumar | director, officer: President and Head of R&D | M-Exempt | Acquired | 19,021 | $1.71 |